Items Tagged ‘asco’

December 8th, 2016

Should HER2 Testing Be Routinely Performed in Patients with Gastric Cancer?

By

The short answer is yes! New evidence-based guidelines for human epidermal growth factor receptor 2 (HER2) testing in advanced gastric and gastroesophageal adenocarcinoma (GEA) have been released jointly by the College of American Pathologists (CAP), American Society for Clinical Pathology (ASCP), and American Society of Clinical Oncology (ASCO). Currently, HER2 is the only marker that can be […]

View full entry

Tags: adenocarcinoma, American Society for Clinical Pathology, and American Society of Clinical Oncology, asco, ASCP, CAP, College of American Pathologists, Esophageal Cancer, for human epidermal growth factor receptor 2, Gastric Cancer, Gastroesophageal cancer, HER2 testing


December 5th, 2016

ASCO Recommends Early Integration of Palliative Care for Advanced Cancers

By

The American Society of Clinical Oncology (ASCO) has updated its guidelines on the integration of palliative care for patients diagnosed with advanced cancer, as well as their caretakers. In essence, the guidelines state that palliative care should be administered as early as possible for all patients diagnosed with advanced cancers, alongside their active treatment, as […]

View full entry

Tags: active treatment, advanced cancer, All Cancer Types, asco, caregiver, guidelines, News, Palliative care, quality of life, Types of Cancer


August 22nd, 2016

SGO, ASCO Issue New Guidelines for Ovarian Cancer Treatment

By

A new joint clinical practice guideline from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) states that neoadjuvant chemotherapy (NACT) is the optimal first-line treatment for some women who have newly diagnosed advanced ovarian cancer. While the standard of care in this setting is primary cytoreductive surgery (PCS) followed […]

View full entry

Tags: advanced, asco, cytoreductive surgery, epithelial, metastatic, NACT, News, Ovarian Cancer, SGO, Stage II-IV Ovarian Cancer


July 21st, 2016

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma

By

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those treated with Taflinar only. These results were presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Advanced melanoma refers to skin […]

View full entry

Tags: 2016, advanced, asco, BRAFV600E/K mutation, COMBI-d trial, dabrafenib, kinase inhibitors, mekinist, Melanoma, News, Stage IV Melanoma, Taflinar


July 11th, 2016

Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia

By

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Chronic lymphocytic leukemia is the most common form of adult leukemia. The American […]

View full entry

Tags: 2016, asco, Bruton’s tyrosine kinase, Chronic Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, CLL, early-stage, ibrutinib, imbruvica, Leukemia, News


June 28th, 2016

Novel Antibody Improves Survival in Advanced Stomach Cancer

By

The novel agent, IMAB362, which stimulates the immune system to attack a certain protein expressed by many stomach cancer cells, has demonstrated a significant improvement in survival compared to standard therapy among patients with this disease. These results were presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Stomach cancer, […]

View full entry

Tags: 2016, advanced, asco, Gastric Cancer, GEJ cancer, IMAB362, News, Stages III-IV Gastric Cancer, stomach cancer


June 27th, 2016

Stent Placement Reduces Need for Stoma in Some Colorectal Cancers

By

The placement of a stent as initial emergency treatment for colon obstruction reduces the need for a stoma without adversely affecting outcomes for patients with potentially curable colorectal cancer. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Colorectal cancer remains the second leading cause of […]

View full entry

Tags: 2016, Adjuvant (I-III, A-C) Colon Cancer, asco, Colon Cancer, curable, News, obstruction, stent, stoma


June 20th, 2016

CAR Therapy Effective in Advanced Lymphoma

By

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types of lymphomas. This type of treatment is continuing to produce impressive results, and is demonstrating effectiveness in several different types […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, asco, CAR, CAR T, chimeric antigen receptor, Follicular Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Leukemia, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma


June 7th, 2016

Jakafi Significantly Improves Long-Term Outcomes in Myelofibrosis

By

The agent Jakafi® (ruxolitinib) has demonstrated significant improvements in long-term outcomes for patients diagnosed with myelofibrosis. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Myelofibrosis (MF) is a type of blood cancer known as a myeloproliferative neoplasm that is chronic and progressive in nature. It involves the […]

View full entry

Tags: 2016, asco, blood cancer, COMFORT 1, jakafi, myelofibrosis, Myeloproliferative Neoplasms MPN, News


June 7th, 2016

Temodar® After Radiation Improves Survival in Anaplastic Gliomas

By

The use of the chemotherapy agent Temodar (temozolomide) following radiation therapy significantly improves time to cancer progression and overall survival among patients with newly diagnosed anaplastic glioma without 1p/19q co-deletions. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Anaplastic gliomas are a type of brain […]

View full entry

Tags: 2016, Anaplastic gliomas, asco, Brain Cancer, CATNON trial, General Brain Cancer, News, radiation therapy, Temodar, temozolomide


June 7th, 2016

Abemaciclib Promising in Advanced Breast Cancer

By

The investigative agent abemaciclib, which is still in clinical trials, appears promising in providing anti-cancer activity among patients with metastatic breast cancer that has progressed following several prior therapies. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology. Metastatic breast cancer (MBC) refers to cancer that has […]

View full entry

Tags: 2016, abemaciclib, asco, Breast Cancer, HER2-negative, HR-positive, MBC, Metastatic Breast Cancer, MONARCH 1 trial, News


June 6th, 2016

IMAB362 Leads to Longer Remission and Better Survival in Gastric Cancer

By

The results of a novel treatment for gastric cancer with the investigational antibody IMAB362 were released at the American Society of Clinical Oncology (ASCO) this week. IMAB362 led to extended remissions and prolonged survival for patients with advanced gastric cancers. Gastric cancer refers to cancer of the stomach. The American Cancer Society estimates that 24,590 […]

View full entry

Tags: 2016, antibody, asco, capecitabine, claudin, Ellence, eloxatin, epirubicin, Gastric Cancer, gastric tumors, IMAB362, longer remission


June 6th, 2016

A New Standard of Care of Treatment for Resectable Pancreatic Cancer?

By

According to experts at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting the European Study Group for Pancreatic Cancer (ESPAC)-4 has presented results that will change the management of pancreatic cancer. Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the […]

View full entry

Tags: 2016, asco, capecitabine, ESPAC-4, European Study Group for Pancreatic Cancer, gemcitabine, gemzar, immunotherapy, mesothelin-directed cells, News, Pancreatic Cancer, Xeloda


June 6th, 2016

Two-Drug Immunotherapy Deemed Safe for Small Cell Lung Cancer Patients, Moffitt Study Shows

By

Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that has no effective treatment options. A new Moffitt Cancer study being presented at the ASCO Annual Meeting in Chicago and published in The […]

View full entry

Tags: 2016, asco, Checkmate 032, immunotherapy, ipilmumab, Lung Cancer, Lung Cancer - Small Cell, molecule PD-1, News, nivolumab, sclc, small cell lung cancer


May 25th, 2016

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk

By

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing and genetic counseling service, today announced its expansion into the oncology market, with a focus on advancing cancer risk screening and helping cancer prevention efforts. Counsyl’s […]

View full entry

Tags: asco, ASCO16, ASCO2016, BRCAtesting, breast, Breast Cancer, breastcancerawareness, colon, Colon Cancer, DNAtesting, genetic testing, inherited cancer screen